United Therapeutics Rest-of-World — Total long-lived assets increased by 35.0% to $15.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 35.0%, from $11.70M to $15.80M.
An increase suggests expanding international operational capacity or investment in foreign market infrastructure, while a decrease may indicate asset divestiture or depreciation exceeding new capital investment.
This metric represents the total value of non-current assets held by the company within its international geographic seg...
Peers in the pharmaceutical industry typically report this as part of geographic segment disclosures, often correlated with the maturity of international distribution networks.
uthr_segment_rest_of_world_total_long_lived_assets| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $12.80M | $12.60M | $12.00M | $11.70M | $15.80M |
| QoQ Change | — | -1.6% | -4.8% | -2.5% | +35.0% |
| YoY Change | — | -1.6% | -4.8% | -2.5% | +35.0% |